Education
About Us
Working with TipRanks
Follow Us
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
ADCT Stock Chart & Stats
$3.90
-$0.05(-2.50%)
At close: 4:00 PM EST
$3.90
-$0.05(-2.50%)
Day’s Range― - ―
52-Week Range$1.05 - $4.80
Previous CloseN/A
Volume185.04K
Average Volume (3M)1.26M
Market Cap
$483.12M
Enterprise Value$389.18M
Total Cash (Recent Filing)$234.74M
Total Debt (Recent Filing)$117.27M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding123,877,110
10 Day Avg. Volume2,177,579
30 Day Avg. Volume1,256,694
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.95
Price to Sales (P/S)2.73
P/FCF Ratio-1.55
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue5.17
Enterprise Value/Gross Profit5.58
Enterprise Value/Ebitda-3.43
Forecast
1Y Price Target
$7.33Price Target Upside87.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsLOTIS-7 showed a very high overall response rate for ZYNLONTA plus glofitamab with many complete responses remaining durable, supporting the regimen's strong efficacy profile in relapsed or refractory disease.
Financial PositionReported loss per share was narrower than prior estimates and balance sheet resources are expected to provide an operational runway into 2H26, reducing near-term financing pressure.
Regulatory PathwayManagement signals a potential confirmatory FDA approval pathway for later-line DLBCL based on LOTIS-5 results, which could enable wider access if regulatory requirements are met.
Bears Say
Competing Front-line TrialsA Phase 3 trial testing glofitamab combined with polatuzumab in the frontline setting could shrink the later-line patient pool and reduce commercial opportunity for the combination.
Market CompetitionAn evolving treatment landscape with multiple emerging regimens could limit adoption of ZYNLONTA plus glofitamab and pressure potential market share.
Pipeline Execution RiskClinical setbacks, delayed approvals, or slower-than-expected market uptake for ADCT-402 and other pipeline candidates could weaken growth prospects and investor confidence.
ADC Therapeutics News
ADCT FAQ
What was ADC Therapeutics Ltd’s price range in the past 12 months?
ADC Therapeutics Ltd lowest stock price was $1.05 and its highest was $4.80 in the past 12 months.
What is ADC Therapeutics Ltd’s market cap?
ADC Therapeutics Ltd’s market cap is $483.12M.
When is ADC Therapeutics Ltd’s upcoming earnings report date?
ADC Therapeutics Ltd’s upcoming earnings report date is Mar 12, 2026 which is in 35 days.
How were ADC Therapeutics Ltd’s earnings last quarter?
ADC Therapeutics Ltd released its earnings results on Nov 10, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.363 by $0.063.
Is ADC Therapeutics Ltd overvalued?
According to Wall Street analysts ADC Therapeutics Ltd’s price is currently Undervalued.
Does ADC Therapeutics Ltd pay dividends?
ADC Therapeutics Ltd does not currently pay dividends.
What is ADC Therapeutics Ltd’s EPS estimate?
ADC Therapeutics Ltd’s EPS estimate is -0.27.
How many shares outstanding does ADC Therapeutics Ltd have?
ADC Therapeutics Ltd has 123,877,110 shares outstanding.
What happened to ADC Therapeutics Ltd’s price movement after its last earnings report?
ADC Therapeutics Ltd reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.363. Following the earnings report the stock price went up 4.208%.
Which hedge fund is a major shareholder of ADC Therapeutics Ltd?
Currently, no hedge funds are holding shares in ADCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ADC Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (87.95% Upside)
$7.33 (87.95% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.99%
Trailing 12-Months
Company Description
ADC Therapeutics Ltd
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
ADCT Company Deck
ADCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted stable revenues, promising clinical trial results, and a strong financial position, offset by a decline in year-over-year revenues and ongoing net loss.View all ADCT earnings summariesADCT Stock 12 Month Forecast
Average Price Target
$7.33
▲(87.95% Upside)
Technical Analysis
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Olema Pharmaceuticals
―
Jade Biosciences
―
Ownership Overview
34.09% Insiders
1.35% Mutual Funds
0.07% Other Institutional Investors
60.38% Public Companies and
Individual Investors